Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease

医学 胃肠病学 非酒精性脂肪肝 内科学 水飞蓟宾 脂肪肝 肝功能 乙型肝炎 体质指数 替诺福韦 恩替卡韦 慢性肝炎 拉米夫定 疾病 免疫学 药理学 病毒 人类免疫缺陷病毒(HIV)
作者
Changtian Su,Qin Yang
出处
期刊:Frontiers in Pharmacology [Frontiers Media]
卷期号:13: 1032789-1032789 被引量:4
标识
DOI:10.3389/fphar.2022.1032789
摘要

Objective: This study aims to investigate the clinical efficacy of Ganshuang granules combined with tenofovir, an antiviral drug, in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease. Methods: A total of 92 patients with chronic hepatitis B combined with non-alcoholic fatty liver who were treated in our Hospital from January 2020 to December 2021 were included as the research objects. According to the method of random number table, the patients were divided into the control group (n = 42) and the treatment group (n = 50). The control group was treated with silibinin meglumine tablets and tenofovir, while the treatment group was treated with Ganshuang granules combined with silybin meglumine tablets and tenofovir. Before and after treatment, liver function index, liver hardness measurement (LSM), controlled attenuation parameter (CAP), HBV-DNA serum load and body mass index (BMI) were observed. Results: Compared with the baseline, ALT, AST and GGT were significantly improved in both groups after treatment (p < 0.05), while TBIL indexes were not significantly different before and after treatment (p > 0.05). Patients in the treatment group had significantly lower ALT and AST index values than the control group at 12 and 24 weeks of treatment (p < 0.05). At 12 and 24 weeks of treatment, the fat attenuation parameters of the two groups were significantly decreased compared with those before treatment, and the difference was statistically significant (p < 0.05). The fat attenuation parameters in the treatment group were significantly lower than those in the control group at 12 and 24 weeks after treatment (p < 0.05). Conclusion: The effect of Ganshuang granule combined with antiviral drugs in the treatment of chronic hepatitis B complicated with non-alcoholic fatty liver is significantly better than that of antiviral drugs alone, which is worthy of clinical recommendation. Systematic Review Registration: https://register.clinicaltrials.gov , identifier NCT05523648.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
谢兰完成签到,获得积分10
1秒前
1秒前
kdby完成签到 ,获得积分10
1秒前
sure发布了新的文献求助10
1秒前
清辉影的应助被ggk采纳,获得150
1秒前
2秒前
温暖的炒饭的应助被Rming采纳,获得20
2秒前
3秒前
huxinyu发布了新的文献求助10
3秒前
gbh的应助被泡泡采纳,获得10
4秒前
伶俐的严青的应助被hxxx123采纳,获得30
4秒前
FashionBoy的应助被徐枘采纳,获得30
4秒前
4秒前
小泉完成签到 ,获得积分10
5秒前
esdeath发布了新的文献求助10
5秒前
阳光问安完成签到 ,获得积分0
5秒前
chen9u0发布了新的文献求助10
7秒前
FashionBoy的应助被桃子汽水采纳,获得10
7秒前
寻风完成签到,获得积分10
8秒前
秋秋发布了新的文献求助10
8秒前
大帅锅完成签到 ,获得积分10
8秒前
8秒前
火星上的长颈鹿完成签到,获得积分10
8秒前
sure完成签到,获得积分10
8秒前
鲨鱼辣椒完成签到,获得积分10
9秒前
昔年完成签到,获得积分10
9秒前
orixero的应助被丁真人采纳,获得10
9秒前
10秒前
王宇洁发布了新的文献求助10
10秒前
12秒前
yinluyv完成签到,获得积分10
12秒前
科研通AI6.4的应助被SurbarLaxce采纳,获得10
13秒前
Cheffe完成签到,获得积分10
13秒前
小二郎的应助被lzh采纳,获得10
13秒前
XZM发布了新的文献求助10
13秒前
Enfant完成签到,获得积分10
13秒前
14秒前
Adanikki完成签到 ,获得积分10
14秒前
14秒前
传奇3的应助被黑色风衣采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183792
求助须知:如何正确求助?哪些是违规求助? 9573020
关于积分的说明 21828776
捐赠科研通 7780959
什么是DOI,文献DOI怎么找? 3434116
关于科研通互助平台的介绍 2558301
邀请新用户注册赠送积分活动 2480611